ImmunoGen — Corporate Update (May 2018)
11 slides from ImmunoGen's corporate update, May 17, 2018
Slide 1: Forward-Looking Statements
FO RW A RD - L OOKI NGS T A T EMENT S This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not limited to, ImmunoGen's expectations related to: the occurrence, timing and outcome of potential pre-clinical, clinical and re
Slide 2: Executing on our highest strategic priority
F O RW A RDI EXECUTING ON OUR HIGHEST STRATEGIC PRIORITY: Patient enrollment completed ahead of schedule Trial continuing as planned following successful pre-specified interim futility analysis Top-line data on-track to be reported in IH19 MIRVETUXIMAB SORAVTANSINE FO R WA R D II Updated data from t
Slide 3: Comprehensive development strategy for mirvetuximab
C O M P R E H E N S I V E D E V E L O P M S T R A T E G Y F O R E N T Establish initial position through single-agent monotherapy in ovarian cancer M I R V E T U X I M A B Expand benefit through combinations in earlier lines ovarian cancer of Broaden use into additional FR-positive solid tumors (NSC
Slide 4: Label expansion: mirvetuximab to become the combination agent of choice
LABEL EXPANSION: MIR V E T U X IMA B BECOME THE COMBINATION AGENT OF CHOICE EN R O LLM EN T: Patients with recurrent platinum-resistant or platinum-sensitive FR-positive ovarian cancer Avastin® is a registered trademark of Genentech Keytruda ® is a registered trademark of Merck 5 C ARB O P L A T I N
Slide 5: Need for effective combinations
N EED FOR EFFE C TI V E C OM BI N ATI ON S C U RREN T T REA T MEN T S F O R B O T H P L A T I N U M - R E S I S T A N T A N D PL A T INU M - S E N S I T I V E O V A R IA N CA NCE R Regimen Chemo/Avastin Regimen Carbo/Gem Carbo/Tax Median age 61 Median age 61 60 Platinum resist 1-2 priors 60% - 1 pri
Slide 6: Avastin expansion cohort
A VA S T I N EXPANSION COHORT AV AS T I N 1 Mirvetuximab in combination with Avastin shows early evidence of anti-tumor activity with durable responses Greatest benefit seen among the subset of patients with medium or high FR expression levels, which is the population being studied in the FORWARD I
Slide 7: Carboplatin mature cohort dose-escalation findings
C A R B O P L AT I N M A T U R E C O H O R T D O S E - E S C A L A T I O N F I N D I N G S in combination with carboplatin Mirvetuximab appears well-tolerated and highly active in patients with recurrent, platinum-sensitive ovarian cancer Further evaluation of this combination in a randomized fashio
Slide 8: Keytruda dose escalation cohort
K E Y T R U D A DOSE ESCALATION COHORT Mirvetuximab in combination with Keytruda shows early evidence of anti-tumor activity with durable responses and favorable tolerability profile Greatest benefit seen among the subset of patients with medium or high FR expression levels, which is the population
Slide 9: Mirvetuximab combinations offer potential to treat more women with ovarian cancer
MI R V E T U X I M A B C O MB I N A T I O N S O F F E R P O T E N T I A L T O T RE A T M O RE W O M E N W IT H O VA RIA N C A NC E R AV AS T I N 1 P L A T I N U M - R E S I S T A N T (n=10) (95% CI 44,98) mPFS not yet reached 1ASCO 2018 O’Malley D., et al.; 2Company data – manuscript in preparation;
Slide 10: Mirvetuximab combinations offer potential to treat more women with ovarian cancer
MI R V E T U X I M A B C O MB I N A T I O N S O F F E R P O T E N T I A L T O C A NC E R 1 T RE A T M O RE W O M E N W IT H O VA RIA N Results have indicated a favorable safety profile with adverse events in-line with known profiles of each agent – full dose of each agent able to be combined Encoura
Slide 11: Mirvetuximab combinations offer potential to treat more women with ovarian cancer
MIRVETUXIMAB COMBINATIONS OFFER POTENTIAL TO TREAT MORE WOMEN WITH OVARIAN CANCER? = Results have indicated a favorable safety profile with adverse events in-line with known profiles of each agent - full dose of each agent able to be combined = Encouraged by early evidence of anti-tumor activity wit